Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkersE Conde, B Angulo, E Izquierdo, et al.
Journal of Chemotherapy (Florence, Italy)|January 31, 2008
Fluorouracil-based chemotherapy in patients with gastrointestinal malignancies: influence of nutritional folate status on toxicityR Alvarez-Cabellos, R Garcia-Carbonero, C Garcia-Lacalle, et al.
Oncology|July 8, 2011
Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumorsP Maroto, R Huddart, X Garcia del Muro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancerM Hidalgo, D Castellano, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1993
CMV front-line chemotherapy in transitional bladder carcinomaL Paz-Ares, P Lianes, M Díaz-Puente, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 2, 2019
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensusD Isla, J de Castro, R García-Campelo, et al.
Seminars in Oncology|January 14, 1998
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancerR Hitt, L Paz-Ares, M Hidalgo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myelomaD Cunningham, L Paz-Ares, S Milan, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2003
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancerC Dittrich, B Coudert, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 24, 1998
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancerD Castellano, P Lianes, L Paz-Ares, et al.
Pageof 9